1. トップ >
  2. Medical Affairs Website >
  3. 神経領域Publication一覧

神経領域Publication一覧

　毎月更新予定
（最終更新：2024/4）

こちらには弊社社員が著者に含まれる論文や、弊社から資金提供・原薬提供などを行った研究論文を掲載しています。

神経領域

2024開く

    ＜英文＞

  • Eating problems in people with dementia with Lewy bodies: associations with various symptoms, and the physician's understanding.

    S. Shinagawa et al., International Psychogeriatrics 2024 Feb 26:1-11.

  • Neuroinflammation following anti-parkinsonian drugs in early Parkinson’s disease: a longitudinal PET study.

    T. Terada et al, Scientific Reports 2024 Feb 27;14(1):4708.

    • ＜和文＞

2023開く

    ＜英文＞

  • Efficacy of Adjunctive Therapy with Zonisamide Versus Increased Dose of Levodopa for Motor Symptoms in Patients with Dementia with Lewy Bodies: The Randomized, Controlled, Non-Inferiority DUEL Study

    M. Ikeda et al. J Alzheimers Dis. 2023;95(1):251-264.

  • Behavioral effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson's disease model mice.

    Sano H et al. Front Aging Neurosci. 2023 Jun 27;15:1221341.

  • Questionnaire survey of satisfaction with medication for five symptom domains of dementia with Lewy bodies among patients, their caregivers, and their attending physicians.

    S Toya et al. Psychogeriatrics. 2023 Jun 25.

  • Correction: Treatment needs of dementia with Lewy bodies according to patients, caregivers, and physicians: a cross-sectional, observational, questionnaire-based study in Japan.

    M.Hashimoto et al. Alzheimers Res Ther. 2023 Jan 5;15(1):4.

    • ＜和文＞

  • Lewy小体型認知症に伴うパーキンソニズムに対するゾニサミド一般使用成績調査：日常診療下でのゾニサミド25mg/日の安全性および有効性の検討

    谷　俊輔 他　脳神経内科, 99巻2号 P.259-273

  • レビー小体型認知症の各症状に対するエキスパート　医師による薬剤処方の実態調査

    橋本 衛 他. Dementia Japan. 2023 37-3

2022開く

    ＜英文＞

  • Treatment needs of dementia with Lewy bodies according to patients, caregivers, and physicians: a cross-sectional, observational, questionnaire-based study in Japan.

    M.Hashimoto et al. Alzheimers Res Ther. 2022 Dec 15;14(1):188.

  • Pretreatment with Zonisamide Mitigates Oxaliplatin-Induced Toxicity in Rat DRG Neurons and DRG Neuron-Schwann Cell Co-Cultures.

    S.Takaku et al. Int J Mol Sci. 2022 Sep 1;23(17):9983.

  • Comparative whole transcriptome analysis of Parkinson's disease focusing on the efficacy of zonisamide.

    T.Naito et al. J Neurol Neurosurg Psychiatry. 2022 May;93(5):509-512.

  • Long-Term Efficacy and Safety of Zonisamide for Treatment of Parkinsonism in Patients With Dementia With Lewy Bodies: An Open-Label Extension of a Phase three Randomized Controlled Trial.

    T.Odawara et al. Am J Geriatr Psychiatry. 2022 Mar;30(3):314-328.

    • ＜和文＞

  • パーキンソニズムを有するレビー小体型認知症患者を対象としたゾニサミド 25 mg/日を長期投与時の有効性と安全性　ー第三相試験のポストホック解析ー

    小田原俊成ら　Dementia Japan. 2022;36(3):496-508.

2021開く

    ＜英文＞

  • Zonisamide improves axial symptoms in dementia with Lewy bodies with parkinsonism: Post hoc analysis of clinical trials.

    Y.Tsuboi et al. eNeurologicalSci. 2021 Dec 7;26:100384.

  • Zonisamide improves wearing off in Parkinson‘s disease without exacerbating dyskinesia: Post hoc analysis of phase 2 and phase 3 clinical trials.

    Y.Tsuboi et al. J Neurol Sci. 2021 Nov15;430:120026.

  • Efficacy and Safety of Zonisamide in Dementia with Lewy Bodies Patients with Parkinsonism: A Post Hoc Analysis of Two Randomized, Double-Blind, Placebo-Controlled Trials.

    K.Hasegawa et al. J Alzheimers Dis. 2021;79:627-637.

    • ＜和文＞

  • ドパミンアゴニストからゾニサミドへの切り替えによるパーキンソン病患者の精神症状及び運動症状への影響

    阿部隆志ら　臨床神経学,2021, 61巻7号 P.449-455

2020開く

    ＜英文＞

  • Zonisamide promotes survival of human-induced pluripotent stem cell-derived dopaminergic neurons in the striatum of female rats.

    Y.Miyawaki et al. J Neurosci Res. 2020 Aug;98(8):1575-1587.

  • Genome-wide association study identifies zonisamide responsive gene in Parkinson's disease patients.

    Pei-Chieng Cha et al. J Hum Genet. 2020 Aug;65(8):693-704.

  • Effect of zonisamide on parkinsonism in patients with dementia with Lewy bodies: A phase 3 randomized clinical trial.

    M.Murata et al. Parkinsonism Relat Disord. 2020 Jul;76:91-97.

  • Zonisamide enhances neurite outgrowth from adult rat dorsal root ganglion neurons, but not proliferation or migration of Schwann cells.

    S.Takaku et al. Histochem Cell Biol. 2020 Mar;153(3):177-184.

  • Zonisamide for Treating Parkinson’s Disease.

    R.Hanajima et al.NeuroPsychopharmacotherapy, 2020 p.1-9

  • Zonisamide ameliorates progression of cervical spondylotic myelopathy in a rat model.

    S.Kanbara et al. Sci Rep. 2020 Aug 4;10(1):13138.

  • Zonisamide ameliorates neuropathic pain partly by suppressing microglial activation in the spinal cord in a mouse model.

    H.Koshimizu et al. Life Sci. 2020 Dec 15;263:118577.

2019開く

    ＜英文＞

  • Comparison of zonisamide with non-levodopa, anti-Parkinson's disease drugs in the incidence of Parkinson's disease-relevant symptoms.

    H.Iwaki et al. J Neurol Sci. 2019 Jul 15;402:145-152.

  • A survey of doctors on diagnosis and treatment of dementia with Lewy bodies: examination and treatment of behavioural and psychological symptoms.

    T.Odawara et al. Psychogeriatrics. 2019 Jul;19(4):310-319.

  • Fact-finding survey on diagnostic procedures and therapeutic interventions for parkinsonism accompanying dementia with Lewy bodies.

    Y.Manabe et al. Psychogeriatrics. 2019 Jul;19(4):345-354.

  • The effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson's disease model mice.

    H.Sano et al. Neurochem Int. 2019 Mar;124:171-180.

    • ＜和文＞

  • Wearing-offを呈するParkinson病患者の実臨床下での処方状況およびゾニサミド50mg/日の安全性・有効性の検討

    谷俊輔ら　脳神経内科, 2019, 91巻3号 P.378-389

2018開く

    ＜英文＞

  • Zonisamide cotreatment delays striatal dopamine transporter reduction in Parkinson disease: A retrospective, observational cohort study.

    K.Ikeda et al. J Neurol Sci.2018 Aug 15;391:5-9.

  • Adjunct zonisamide to levodopa for DLB parkinsonism: A randomized double-blind phase 2 study.

    M.Murata et al. Neurology. 2018 Feb 20;90(8):e664-e672.

  • Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson's Disease.

    S.Ueno et al. Cells. 2018 Dec 29;8(1):14.

  • Zonisamide Enhances Motor Effects of Levodopa, Not of Apomorphine, in a Rat Model of Parkinson's Disease.

    H.Nishijima et al. Parkinsons Dis. 2018 Dec 18;2018:8626783

2017開く

    ＜英文＞

  • Overcoming Obstacles to Drug Repositioning in Japan.

    Y.Nishimura et al. Front Pharmacol. 2017 Oct 11;8:729.

  • Zonisamide inhibits monoamine oxidase and enhances motor performance and social activity.

    M.Uemura et al. Neurosci Res. 2017 Nov;124:25-32.

  • Zonisamide ameliorates levodopa-induced dyskinesia and reduces expression of striatal genes in Parkinson model rats.

    M.Oki et al. Neurosci Res. 2017 Sep;122:45-50.

  • Combination Therapy with Zonisamide and Antiparkinson Drugs for Parkinson's Disease: A Meta-Analysis.

    S. Matsunaga et al. J Alzheimer's Dis. 2017;56(4):1229-1239

    • ＜和文＞

  • Wearing-off現象を発現したパーキンソン病患者に対するゾニサミド50mgの安全性および有効性の検討　長期使用に関する特定使用成績調査の中間報告

    右橋千秋ら　新薬と臨牀, 2017, 66巻12号 P.1493-1509

2016開く

    ＜英文＞

  • Randomized placebo-controlled trial of zonisamide in patients with Parkinson’s disease.

    M.Murata et al. Neurology and Clinical Neuroscience, 2016, 4:10–15

2015開く

    ＜英文＞

  • Influence of Zonisamide on the LTP-like Effect Induced by Quadripulse Transcranial Magnetic Stimulation (QPS).

    N.Tanaka et al. Brain Stimul. 2015 Nov-Dec;8(6):1220-2.

  • Zonisamide improves wearing-off in Parkinson's disease: A randomized, double-blind study.

    M.Murata et al. Mov Disord. 2015 Sep;30(10):1343-50.

  • Zonisamide suppresses endoplasmic reticulum stress-induced neuronal cell damage in vitro and in vivo.

    S.Tsujii et al. Eur J Pharmacol. 2015 Jan 5;746:301-7

  • Modulation of endoplasmic reticulum stress in Parkinson's disease.

    S.Tsujii et al. Eur J Pharmacol. 2015 Oct 15;765:154-6.

  • Zonisamide enhances neurite elongation of primary motor neurons and facilitates peripheral nerve Regeneration In Vitro and in a Mouse Model.

    H.Yagi et al. PLoS One. 2015 Nov 16;10(11):e0142786.

  • Zonisamide reduces nigrostriatal dopaminergic neurodegeneration in a mouse genetic model of Parkinson's disease.

    H.Sano et al. J Neurochem. 2015 Jul;134(2):371-81.

2014開く

    ＜英文＞

  • Zonisamide regulates basal ganglia transmission via astroglial kynurenine pathway.

    K.Fukuyama et al. Neuropharmacology. 2014 Jan;76 Pt A:137-45.

  • Zonisamide attenuates α-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson's disease.

    S.Arawaka et al. PLoS One. 2014 Feb 20;9(2):e89076

    • ＜和文＞

  • パーキンソン病治療薬トレリーフ(ゾニサミド)について

    村橋豊ら　別冊Bio Clinica, 慢性炎症と疾患, 2014, 3巻1号 P.150-155